Repotrectinib, a newer inhibitor, showed an ORR of 40% to 67% in previously treated ROS1-positive NSCLC patients [100], while another novel ROS1 inhibitor taletrectinib achieved an ORR of 90% in TKI-naive patients [101]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.